Search

Your search keyword '"Im, Gun‐Il"' showing total 509 results
Start Over Author "Im, Gun‐Il"
509 results on '"Im, Gun‐Il"'

15. Emerging Concepts of Endotypes/Phenotypes in Regenerative Medicine for Osteoarthritis

Author

Im, Gun-Il and Moon, Jae-Yeon

Abstract

Osteoarthritis (OA) represents a broad spectrum of different conditions. Our present understanding of phenotypes and endotypes can explain the differences in clinical manifestations, etiology, and underlying pathophysiology. Although this concept was first applied in choosing the right target population for clinical trials of disease-modifying osteoarthritis drugs (DMOADs), given that the regenerative medicine so far has not delivered uniformly successful results in structural improvement in OA, it merits a consideration to introduce the concept of phenotype/endotype in the regenerative medicine for OA toward an effort to find the right patients for these expensive therapeutics. A better understanding of molecular endotypes facilitates defining clinical phenotypes more clearly. Based on this knowledge, these patients may respond better to treatments that can preserve joints, including regenerative medicine. On the other hand, patients who are not expected to benefit from these treatments may receive earlier total joint replacement surgery. This will result in a reduction of healthcare costs, as well as a more effective approach to new drug development. An understanding of phenotypes/endotypes will contribute to the selection of suitable patients for regenerative treatment of OA.

Published
2024
Full Text
View/download PDF

16. Regenerative medicine for early osteoarthritis.

Author

Im, Gun-Il and Henrotin, Yves

Subjects
OSTEOARTHRITIS, REGENERATIVE medicine, DISEASE progression, INDIVIDUALIZED medicine, PHENOTYPES
Abstract

The concept of early osteoarthritis (OA) is based on the expectation that if found and treated in the early stage, the progression of the disease might be arrested before affected joints are irreversibly destroyed. This notion of early OA detection can also bear meaning for regenerative medicine (RM) which is purposed to cure a disease by regenerating the damaged tissue. RM can be a category of disease-modifying osteoarthritis drugs (DMOADs) and provide an attractive treatment for OA, restoring structural damage incurred during the disease by repopulating cells and reconstituting. While cell therapy including the use of stem cells is conflated with RM, it may also comprise gene therapy, exosomes, and other cell or cell-free-derived products. Considering that not all early OA will become advanced OA and that RM has a characteristic of personalized medicine, it would be very important to foretell, even roughly, which patients will progress rapidly and who will favorably respond to regenerative treatment. Subclassification and comprehensive endotyping or phenotyping (E/P) can be very helpful in detecting the population who would benefit from RM as well as rapid progressors who need closer monitoring. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Current status of regenerative medicine in osteoarthritis

Author

Im, Gun-Il

Subjects
Editorial, Impact, Knowledge Translation, Research, Regenerative medicine, Osteoarthritis, Social Media
Abstract

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods. Cite this article: Bone Joint Res 2021;10(2):134–136.

Published
2021

42. Cell‐Membrane‐Derived Nanoparticles with Notch‐1 Suppressor Delivery Promote Hypoxic Cell–Cell Packing and Inhibit Angiogenesis Acting as a Two‐Edged Sword (Adv. Mater. 40/2021)

Author

Kim, Hye‐Seon, primary, Shin, Young Min, additional, Chung, Seyong, additional, Kim, Dahee, additional, Park, Dan Bi, additional, Baek, Sewoom, additional, Park, Jeongeun, additional, Kim, Si Yeong, additional, Kim, Dae‐Hyun, additional, Yi, Se Won, additional, Lee, Songhyun, additional, Lee, Jung Bok, additional, Ko, Ji‐Yun, additional, Im, Gun‐Il, additional, Kang, Mi‐Lan, additional, and Sung, Hak‐Joon, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results